Adiponectin has been shown to have cytoprotective properties, improving both hepatic and peripheral insulin sensitivity and preventing steatosis, inflammation, and necrosis, whereas the inhibition of NFKB1 induces non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC) by sensitizing hepatocytes to undergo spontaneous apoptosis [49]. Here, ADIPOQ is linked to metabolic dysfunction-associated steatohepatitis.